The Catalyst

Most Recent Posts

01.06.14 | By Mark Grayson

This is the first blog post in a series of responses to Luke Timmerman’s Xconomy article, “12 Things the Pharma Industry Can Do to Rebuild Real Public Trust,” in which he says the pharmaceutical industry isn’t doing enough to deliver “big health advances.”

01.06.14 | By Kristin Van Goor

The assessment of the benefit-risk balance of a medicine is a key component of the drug development and regulatory review process. This assessment is also an important determination that each patient and doctor must make when choosing a treatment strategy.

12.28.13

The best health stems from the best information, and this includes biopharmaceutical information-sharing with physicians and patients. As the creators of many of the medicines we all rely upon, the companies have the most up to date knowledge on safety and benefit/risk, making conversations with prescribing physicians imperative to better care.

12.20.13 | By Jay Taylor

What provides two-thirds of the Trans-Pacific Partnership (TPP) agreement’s total economic benefits? The answer is intellectual property-intensive manufacturing industries.

12.19.13

Rather than trying to uncover what’s at play behind a woman’s struggle to pay for the costs of her leukemia medicine, last night’s ABC World News with Diane Sawyer barely scratched the surface of a complex issue. The result: a one-sided, overly simplistic view of the cost of cancer medicines in the United States.

12.17.13 | By John Castellani

When we launched Conversations in June of this year, our goal was to blend formal contributors with an ongoing opportunity for experts and thought leaders to weigh in on a broad range of high-level policy topics. The forum has been a tremendous success.

12.17.13 | By Mit Spears

Last week, I had the opportunity to participate in a panel discussion at the Elsevier Business Intelligence FDA/CMS Summit entitled, “Beyond the Label.” 

12.16.13

PhRMA Pushes Back on New York Times

12.16.13

Worth a read are the commentaries surrounding the latest Room for Debate question posed by the New York Times; it’s a good snapshot into the various views on the issue of biopharmaceutical and physician interaction.

12.13.13

I walked away from Friday morning’s “Research in Your Backyard:  Pharmaceutical Clinical Trials in Minnesota” breakfast meeting in Minneapolis mightily impressed with two things: Frank Jaskulke’s very maroon and gold running shoes –a great contrast with the conservative suit the Minnesota life sciences thought leader was wearing – and w

12.13.13 | By Kaelan Hollon

Discovering and developing new treatments for the world’s most pressing health challenges helps inspire the work of innovators across the biopharmaceutical sector. More importantly, it’s our end-goal to ensure that patients around the world can obtain such innovative treatments in a timely manner.

12.13.13

It’s hard to see the silver lining when it comes to cancer, as many view the disease as a devastating prognosis. And while cancer can take a serious toll on patients and their loved ones, they should know that tremendous strides are being made in the research and development of new cancer medicines that are allowing patients to lead longer, healthier lives.

12.12.13 | By Preet Bilinski

Recently the 26th Anniversary of World AIDS Day was celebrated, along with the remarkable progress that has been made against this disease.

12.12.13

Between Lake Champlain and the Green Mountains of Vermont, the Burlington area houses one of the economic cores of the region.  Yesterday’s "Research in Your Backyard," event brought together researchers, doctors and patients, and focused on the biopharmaceutical industry’s contributions to the state’s prosperity through

12.11.13

Over the weekend, the Washington Post ran a story about the price of prescription medicines offered through the Medicare Part B program, a benefit that provides coverage for outpatient administered medicines.

Pages